Hypofractionated stereotactic boost in intermediate risk prostate carcinoma: Preliminary results of a multicenter phase II trial (CKNO-PRO).
Fiche publication
Date publication
janvier 2017
Journal
PloS one
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEIFFERT Didier
Tous les auteurs :
Pasquier D, Nickers P, Peiffert D, Maingon P, Pommier P, Lacornerie T, Martinage G, Tresch E, Lartigau E
Lien Pubmed
Résumé
Dose escalation may improve curability in intermediate-risk prostate carcinoma. A multicenter national program was developed to assess toxicity and tumor response with hypofractionated stereotactic boost after conventional radiotherapy in intermediate-risk prostate cancer.
Mots clés
Aged, Aged, 80 and over, Humans, Male, Middle Aged, Prostatic Neoplasms, radiotherapy, Radiotherapy, Intensity-Modulated
Référence
PLoS ONE. 2017 ;12(11):e0187794